Tumor Markers (Online CE Course)

(based on 462 customer ratings)

Jack Maggiore, PhD, MLS(ASCP)
Reviewer: Kevin F. Foley, PhD, DABCC, MT, SC, and Lisa Dewey, MT(ASCP)

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 176 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote

This course is intended to provide the basic information necessary regarding tumor markers and how they are used to detect, diagnose, and provide a prognosis of various cancers, as well as to provide an increased understanding of the many emerging biomarkers.

See all available courses

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 1.5 hour(s)
Approved through 10/31/2024
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Clinical Chemistry/UA/Toxicology): 1.5 hour(s)
Approved through 10/31/2024

Objectives

  • Describe the features of a measurand that make for an ideal tumor marker.
  • Delineate the factors that limit the utility of a component as a tumor marker.
  • Correlate the presence of a tumor marker with its associated affected organ system.
  • Differentiate between carbohydrate-rich tumor markers, protein-rich tumor markers, enzymatic tumor markers, and oncofetal antigens.
  • List some of the emerging tumor markers for assessing breast cancer response to therapy and breast cancer risk.

Customer Ratings

(based on 462 customer ratings)

Course Outline

Click on the links below to preview selected pages from this course.
  • Definitions and Background
    • Key Definitions
      • Cancer
      • Tumor Marker
    • Background
      • Cancer Prevalence and Relative Risk
      • Cancer Prevalence - New Cancer Cases by Site
      • Cancer Predispositions
      • Early Detection is Crucial
      • Which statement would NOT fit the definition of a tumor marker?
  • The Ideal Tumor Marker
    • Specificity
      • The Ideal Tumor Marker Would Have 100% Specificity
    • Sensitivity
    • Concentration and Tumor Mass
      • The Ideal Tumor Marker Would Be Indicative of Tumor Mass
    • Analytical Aspects
      • The Ideal Tumor Marker Would be Detectable in Blood or Biological Fluids
      • The Ideal Tumor Marker Would be Adaptable to Laboratory Analysis
      • Ideally, for a tumor marker to be considered as a screening tool, it should be consistently elevated at early stages of disease so that the diagnostic...
      • Reference Values
    • Reality
  • Examples of Tumor Markers
      • Components
    • Hormones
    • Specific Proteins
      • Specific Proteins as Tumor Markers
      • Specific Proteins as Tumor Markers - Monoclonal Immunoglobulins
      • Specific Proteins as Tumor Markers - Diagnostic Utility
      • The detection of an immunoglobulin clone, such as IgM, is ALWAYS associated with a malignant condition, such as a multiple myeloma.
    • Enzymes
    • Carbohydrate Markers
    • Blood Group Antigen-Related Cancer Markers
      • Blood Group Antigens as Tumor Markers
      • CA 19-9
    • Receptors
    • Oncofetal Antigens
    • Mutations of Tumor Suppressor Genes
      • Breast Cancer Susceptibility Proteins
  • References

Additional Information

Level of instruction: Beginning
 
Intended audience:  Medical laboratory scientists, medical technologists, and technicians. This course is also appropriate for medical laboratory science students and pathology residents.
 
Author information: Jack A. Maggiore, PhD, MT(ASCP) is an Assistant Professor and Associate Laboratory Director of the Core Laboratory Operations and Point of Care Testing at Loyola University Medical Center in Maywood, Illinois. Dr. Maggiore is a medical technologist, certified by the ASCP, with a Master of Science in Clinical Chemistry and Doctorate in Pathology from the University of Illinois. His expertise includes clinical instrumentation, method development and validation, quality assurance, medical device clinical trials, and scientific regulatory affairs. His clinical research interests include the development of novel biomarkers for chronic diseases using blood spots and other non-conventional samples. Dr. Maggiore holds several medical device patents, has authored more than fifty peer-reviewed and invited publications and textbook chapters, and has presented his research findings at international scientific society meetings. Dr. Maggiore's mission is to work with healthcare professionals to empower consumers to take a more active role in their health maintenance.
 
Reviewer Information:  Kevin F. Foley, PhD, DABCC, MT, SC, is the director of clinical pathology for the Kaiser Permanente Northwest region. He also teaches clinical chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina.
 
Reviewer information: Lisa Dewey, MLS(ASCP) is the Quality Manager at Doctor's Data, Inc. and has been a medical technologist since 1990. She obtained a BS in Clinical Laboratory Science from the University of Illinois at Chicago. Lisa has experience working in various specialties in hospital and clinic laboratories, research & development, laboratory management, and a commercial laboratory specializing in dried blood spot testing.
 
Course Description: This course is intended to provide the basic information necessary regarding tumor markers and how they are used

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 176 CE courses, most popular
$109Add to cart
Pick Your Courses
Up to 8 CE hours
$55Add to cart
Individual course$25Add to cart
Need multiple seats for your university or lab? Get a quote
Agarose Gel Electrophoresis


CSF plasma cell Multiple  2


H&E liver biopsy of a hepatocelluar carcinoma 350


lungs2


Plasma cells.  Sheets of plasma cells, as seen in this field of view, are abnormal.  Multiple myeloma must be ruled out. EMHCP417070


Parathyroid Hormone as a Tumor Marker